原发性肝癌综合介入治疗现状与困惑

梁宏元; 卢再鸣

doi:10.3969/j.issn.1001-5256.2016.01.006

原发性肝癌综合介入治疗现状与困惑

DOI: 10.3969/j.issn.1001-5256.2016.01.006

中国医科大学附属盛京医院放射科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2959
- HTML全文浏览量: 35
- PDF下载量: 599
- 被引次数: 0
出版历程
- 收稿日期: 2015-11-16
- 出版日期: 2016-01-20

Current status and confusion in comprehensive interventional therapy for hepatocellular carcinoma

Department of Radiology,China Medical University Shengjing Hospital

摘要

摘要: 由于起病隐匿,肝癌发现时仅有20%~30%的患者有机会接受外科切除或肝移植治疗。目前,介入治疗已成为中期和部分晚期肝癌的首选方案,并且越来越多的学者认识到肝癌综合介入治疗的重要性和必要性。以经肝动脉化疗栓塞术(TACE)为主,联合多种方法(TACE联合局部治疗、TACE序贯手术治疗、TACE联合全身治疗)的综合介入治疗模式使得肝癌治疗手段更加丰富且疗效更佳。但联合治疗的适应证、时机选择以及治疗后复发、转移等问题仍需要未来进一步探索和研究。
- 肝肿瘤 /
- 放射学,介入性 /
- 化学栓塞,治疗性 /
- 综合疗法
Abstract: In recent years,hepatocellular carcinoma( HCC) has become the second leading cause of cancer- related death worldwide. Due to the insidious onset of this disease,only 20%- 30% of the patients with HCC have the opportunity for surgical resection or liver transplantation. At present,interventional therapy has become the first choice for patients with intermediate- stage HCC and some patients with late- stage HCC,and more and more scholars have realized the importance and necessity of comprehensive interventional therapy for HCC. The comprehensive interventional therapy of transcatheter arterial chemoembolization( TACE) in combination with various methods( TACE combined with local treatment,TACE sequential surgery,or TACE combined with systemic treatment) provides many therapeutic approaches and achieves good therapeutic effects. However,the indications,timing,and recurrence and metastasis after treatment for such combination therapies await further investigation.
- liver neoplasms /
- radiology,interrentional /
- chemoembolization,therapeutic /
- combined modality therapy

HTML全文

参考文献(47)

[1]World Health Organization(WHO).Global battle against cancer won't be won with treatment alone-effective prevention measures urgently needed to prevent cancer crisis[J].Cent Eur J Public Health,2014,22(1):23,28.

[2]LLOVET JM,BURROUGHS A,BRUIX J.Hepatocellular carcinoma[J].Lancet,2003,362(9399):1907-1917.

[3]CABRERA R,NELSON DR.Review article:the management of hepatocellular carcinoma[J].Aliment Pharmacol Ther,2010,31(4):461-476.

[4]SCHLACHTERMAN A,CRAFT WW Jr,HILGENFELDT E,et al.Current and future treatments for hepatocellular carcinoma[J].World J Gastroenterol,2015,21(28):8478-8491.

[5]HATANAKA Y,YAMASHITA Y,TAKAHASHI M,et al.Unresectable hepatocellular carcinoma:analysis of prognostic factors in transcatheter management[J].Radiology,1995,195(3):747-752.

[6]MATSUI O.A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma[J].N Engl J Med,1995,332(19):1256-1261.

[7]LLOVET JM,REAL MI,MONTANA X,et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet,2002,359(9319):1734-1739.

[8]LO CM,NGAN H,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171.

[9]MURATA S,MINE T,SUGIHARA F,et al.Interventional treatment for unresectable hepatocellular carcinoma[J].World J Gastroenterol,2014,20(37):13453-13465.

[10]KANAZAWA S.Current status of interventional oncology[J].Int J Clin Oncol,2012,17(4):299-300.

[11]KINOSHITA A,ONODA H,FUSHIYA N,et al.Staging systems for hepatocellular carcinoma:current status and future perspectives[J].World J Hepatol,2015,7(3):406-424.

[12]LLOVET JM,DI BISCEGLIE AM,BRUIX J,et al.Design and endpoints of clinical trials in hepatocellular carcinoma[J].J Natl Cancer Inst,2008,100(10):698-711.

[13]FORNER A,LLOVET JM,BRUIX J.Hepatocellular carcinoma[J].Lancet,2012,379(9822):1245-1255.

[14]PISCAGLIA F,BOLONDI L.The intermediate hepatocellular carcinoma stage:should treatment be expanded?[J].Dig Liver Dis,2010,42(Suppl 3):s258-s263.

[15]RAOUL JL,SANGRO B,FORNER A,et al.Evolving strategies for the management of intermediate-stage hepatocellular carcinoma:available evidence and expert opinion on the use of transarterial chemoembolization[J].Cancer Treat Rev,2011,37(3):212-220.

[16]DUFOUR JF,BARGELLINI I,DE MARIA N,et al.Intermediate hepatocellular carcinoma:current treatments and future perspectives[J].Ann Oncol,2013,24(Suppl 2):ii24-ii29.

[17]LAMMER J,MALAGARI K,VOGL T,et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:results of the PRECISION V study[J].Cardiovasc Intervent Radiol,2010,33(1):41-52.

[18]SIEGHART W,HUCKE F,PINTER M,et al.The ART of decision making:retreatment with transarterial chemoembolization in patients withhepatocellular carcinoma[J].Hepatology,2013,57(6):2261-2273.

[19]European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol,2012,56(4):908-943.

[20]YAU T,TANG VY,YAO TJ,et al.Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma[J].Gastroenterology,2014,146(7):1691-1700.

[21]KUDO M.Real practice of hepatocellular carcinoma in Japan:conclusions of the Japan Society of Hepatology 2009 Kobe Congress[J].Oncology,2010,78(Suppl 1):180-188.

[22]WILLATT JM,FRANCIS IR,NOVELLI PM,et al.Interventional therapies for hepatocellular carcinoma[J].Cancer Imaging,2012,12:79-88.

[23]LU Z,WEN F,GUO Q,et al.Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma:a meta-analysis of randomized-controlled trials[J].Eur J Gastroenterol Hepatol,2013,25(2):187-194.

[24]NI JY,LIU SS,XU LF,et al.Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma:a meta-analysis[J].J Cancer Res Clin Oncol,2013,139(4):653-659.

[25]FU Y,ZHAO X,YUN Q,et al.Transarterial chemoembolization(TACE)plus percutaneous ethanol injection(PEI)for the treatment of unresectable hepatocellular carcinoma:a meta-analysis of randomized controlled trials[J].Int J Clin Exp Med,2015,8(7):10388-10400.

[26]KIM J,CHUNG DJ,JUNG SE,et al.Therapeutic effect of highintensity focused ultrasound combined with transarterial chemoembolisation for hepatocellular carcinoma<5 cm:comparison with transarterial chemoembolisation monotherapy-preliminary observations[J].Br J Radiol,2012,85(1018):e940-e946.

[27]MORIMOTO M,NUMATA K,KONDOU M,et al.Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma:a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization[J].Cancer,2010,116(23):5452-5460.

[28]PENG S,YANG QX,ZHANG T,et al.Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma[J].Asian Pac J Cancer Prev,2014,15(13):5155-5160.

[29]HUO YR,ESLICK GD.Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma:a systematic review and meta-analysis[J].JAMA Oncol,2015,1(6):756-765.

[30]JEONG Y,YOON SM,HAN S,et al.Propensity score matching analysis of changes in alpha-fetoprotein levels after combined radiotherapy and transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus[J].PLoS One,2015,10(8):e0135298.

[31]YAO FY,KERLAN RK JR,HIROSE R,et al.Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation:an intention-to-treat analysis[J].Hepatology,2008,48(3):819-827.

[32]CUCCHETTI A,CESCON M,BIGONZI E,et al.Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy[J].Liver Transpl,2011,17(11):1344-1354.

[33]BELGHITI J,CARR BI,GREIG PD,et al.Treatment before liver transplantation for HCC[J].Ann Surg Oncol,2008,15(4):993-1000.

[34]SCHWARTZ M,ROAYAIE S,UVA P.Treatment of HCC in patients awaiting liver transplantation[J].Am J Transplant,2007,7(8):1875-1881.

[35]LLOVET JM,MAS X,APONTE JJ,et al.Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation[J].Gut,2002,50(1):123-128.

[36]BOUCHARD-FORTIER A,LAPOINTE R,PERREAULT P,et al.Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation:a retrospective study[J].Int J Hepatol,2011,2011:974514.

[37]RAMPONE B,SCHIAVONE B,MARTINO A,et al.Current management strategy of hepatocellular carcinoma[J].World J Gastroenterol,2009,15(26):3210-3216.

[38]GIGLIA JL,ANTONIA SJ,BERK LB,et al.Systemic therapy for advanced hepatocellular carcinoma:past,present,and future[J].Cancer Control,2010,17(2):120-129.

[39]CHEN KW,OU TM,HSU CW,et al.Current systemic treatment of hepatocellular carcinoma:a review of the literature[J].World J Hepatol,2015,7(10):1412-1420.

[40]PAWLIK TM,REYES DK,COSGROVE D,et al.PhaseⅡtrial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma[J].J Clin Oncol,2011,29(30):3960-3967.

[41]PARK JW,KOH YH,KIM HB,et al.PhaseⅡstudy of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma[J].J Hepatol,2012,56(6):1336-1342.

[42]CHUNG YH,HAN G,YOON JH,et al.Interim analysis of START:study in Asia of the combination of TACE(transcatheter arterial chemoembolization)with sorafenib in patients with hepatocellular carcinoma trial[J].Int J Cancer,2013,132(10):2448-2458.

[43]LENCIONI R,LLOVET JM,HAN G,et al.Sorafenib or placebo in combination with transarterial chemoembolization(TACE)with doxorubicin-eluting beads(DEBDOX)for intermediate stage hepatocellular carcinoma(HCC):phaseⅡ,randomized,doubleblind SPACE trial[J].J Clin Oncol,2012,30(Suppl 4):154.

[44]QU XD,CHEN CS,WANG JH,et al.The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma[J].BMC Cancer,2012,12:263.

[45]SACHDEVA M,CHAWLA YK,ARORA SK.Immunology of hepatocellular carcinoma[J].World J Hepatol,2015,7(17):2080-2090.

[46]YANG HI,LU SN,LIAW YF,et al.Hepatitis B e antigen and the risk of hepatocellular carcinoma[J].N Engl J Med,2002,347(3):168-174.

[47]DAVIS CR.Interventional radiological treatment of hepatocellular carcinoma[J].Cancer Control,2010,17(2):87-99.

施引文献

资源附件(0)

访问统计

本文二维码

计量

文章访问数: 2959
HTML全文浏览量: 35
PDF下载量: 599
被引次数: 0

用微信扫码二维码

分享至好友和朋友圈

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

原发性肝癌综合介入治疗现状与困惑

DOI: 10.3969/j.issn.1001-5256.2016.01.006

计量

Current status and confusion in comprehensive interventional therapy for hepatocellular carcinoma

计量

目录

留言板

原发性肝癌综合介入治疗现状与困惑

DOI: 10.3969/j.issn.1001-5256.2016.01.006

计量

出版历程

Current status and confusion in comprehensive interventional therapy for hepatocellular carcinoma

计量

出版历程

目录

关于本刊

投稿指南

在线期刊

肝胆学院

指南共识